A Growth Differentiation Factor 15 Receptor Agonist in Randomized Placebo-Controlled Trials in Healthy or Obese Persons
The Journal of Clinical Endocrinology & Metabolism · 18.02.2025 · 110 (3) · 771-786
DOI: 10.1210/clinem/dgae550 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 16.08.2024. Verfasst von William B Smith und 16 weiteren Autor:innen. Beteiligte Einrichtung: Alliance for Multispecialty Research, LLC, Knoxville, TN 37909, USA. Hauptthemen laut MEDLINE: Obesity, Growth Differentiation Factor 15, Anti-Obesity Agents. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Novartis Biomedical Research.
Abstract (Originalsprache)
Background
Growth differentiation factor 15 (GDF15), a divergent member of the TGF-β superfamily, signals via the hindbrain glial-derived neurotrophic factor receptor alpha-like and rearranged during transfection receptor co-receptor (GFRAL-RET) complex. In nonclinical species, GDF15 is a potent anorexigen leading to substantial weight loss. MBL949 is a half-life extended recombinant human GDF15 dimer.
Methods
MBL949 was evaluated in multiple nonclinical species, and then in humans, in 2 randomized and placebo-controlled clinical trials. In the phase 1, first-in-human, single ascending dose trial, MBL949 or placebo was injected subcutaneously to overweight and obese healthy volunteers (n = 65) at doses ranging from 0.03 to 20 mg. In phase 2, MBL949 or placebo was administered subcutaneously every other week for a total of 8 doses to obese participants (n = 126) in 5 different dose regimens predicted to be efficacious based on data from the phase 1 trial.
Results
In nonclinical species, MBL949 was generally safe and effective with reduced food intake and body weight in mice, rats, dogs, and monkeys. Weight loss was primarily from reduced fat, and metabolic endpoints improved. A single ascending dose study in overweight or obese healthy adults demonstrated mean terminal half-life of 18 to 22 days and evidence of weight loss at the higher doses. In the phase 2, weight loss was minimal following biweekly dosing of MBL949 for 14 weeks. MBL949 was safe and generally tolerated in humans over the dose range tested, adverse events of the gastrointestinal system were the most frequent observed.
Conclusion
The prolonged half-life of MBL949 supports biweekly dosing in patients. MBL949 had an acceptable safety profile. The robust weight loss observed in nonclinical species did not translate to weight loss efficacy in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Alliance for Multispecialty Research, LLC, Knoxville, TN 37909, USA.
- Altasciences Clinical Los Angeles, Inc., Cypress, CA 90630, USA.
- Novartis Biomedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland.
- Novartis Biomedical Research, Cardiovascular, Renal and Metabolic, Cambridge, MA 02139, USA.
- Novartis Pharmaceuticals Corporation, Cardiovascular, Renal and Metabolic, East Hanover, NJ 07936, USA.
ORCID-Profile: William B Smith, David Nguyen, Timothy Clough, Jül Schofield, Mark R Kagan, Jill Kompa, YanLing He, Eleftheria Maratos-Flier, Joanna Jamontt, Linh Vong, Chad D Schwartzkopf, Aimee R Usera, Christopher J O'Donnell, Kurt A Heldwein, Ryan S Streeper, Allison B Goldfine
Förderung
- Novartis Biomedical Research
Zitieren
APA
Smith, W. B., Nguyen, D., Clough, T., Schofield, J., Kagan, M. R., Kompa, J., He, Y., Maratos-Flier, E., Jamontt, J., Vong, L., Schwartzkopf, C. D., Layne, J. D., Usera, A. R., O'Donnell, C. J., Heldwein, K. A., Streeper, R. S., & Goldfine, A. B. (2025). A Growth Differentiation Factor 15 Receptor Agonist in Randomized Placebo-Controlled Trials in Healthy or Obese Persons. The Journal of Clinical Endocrinology & Metabolism, 110(3), 771-786. https://doi.org/10.1210/clinem/dgae550
Vancouver
Smith WB, Nguyen D, Clough T, Schofield J, Kagan MR, Kompa J, et al. A Growth Differentiation Factor 15 Receptor Agonist in Randomized Placebo-Controlled Trials in Healthy or Obese Persons. The Journal of Clinical Endocrinology & Metabolism. 2025;110(3):771-786. doi:10.1210/clinem/dgae550
BibTeX
@article{Smith2025,
author = {Smith, William B and Nguyen, David and Clough, Timothy and Schofield, Jül and Kagan, Mark R and Kompa, Jill and He, YanLing and Maratos-Flier, Eleftheria and Jamontt, Joanna and Vong, Linh and Schwartzkopf, Chad D and Layne, Joseph D and Usera, Aimee R and O'Donnell, Christopher J and Heldwein, Kurt A and Streeper, Ryan S and Goldfine, Allison B},
title = {A Growth Differentiation Factor 15 Receptor Agonist in Randomized Placebo-Controlled Trials in Healthy or Obese Persons},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {3},
pages = {771--786},
doi = {10.1210/clinem/dgae550}
}
EUVIMED